Welcome! Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Please take a moment to confirm your subscription below so we can ensure these updates reach your inbox.
Confirm Your Subscription Here
The Earnings360 Team
Monday's Bonus Story Why GRAIL Stock Could Be Biotech's Next Big BreakoutWritten by Bridget Bennett. Published 11/19/2025. 
Key Points - Insider buying is a reliable signal in market pullbacks, offering long-term confidence amid short-term volatility.
- Biotech stock GRAIL is one to watch, with its breakthrough cancer detection technology nearing FDA approval.
- Despite economic concerns, the American Dream is still attainable through long-term investing, saving, and strategic financial choices.
Retail investors are understandably on edge after several sessions of market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we’re still in one of the best eras in history to build wealth—especially if you think long term and stick to time-tested principles. According to Green, this pullback isn't as severe as it may feel. "Just last Wednesday the Dow hit an all-time high," he noted, adding that the recent selling pressure reflects valuation concerns and uncertainty about interest rates rather than any fundamental breakdown. Why the Market Pulled Back What I've uncovered about the true impact of President Trump's tariffs and DOGE initiative has left me deeply troubled. As someone who worked inside the Federal Reserve system and managed billions for America's wealthiest families, I recognize the warning signs others miss. I urge you to see my urgent message immediately. The window for preparation isn't just closing — it's slamming shut. Watching this may be the most consequential few minutes you spend this year. Green attributes the dip to two main concerns. First, investors are starting to question elevated tech and AI valuations, particularly as earnings season brings those expectations into focus. Second, inflation data and slower hiring have dimmed hopes that the Fed will cut rates in December. With the central bank stressing a "data-dependent" stance, markets are less certain that rate relief is coming this year. Why Selling Now Might Be the Wrong Move Instead of trying to predict next week's moves, Green encourages investors to zoom out. He calls himself "a long-term optimist" and points out that historically the market's trend is up and to the right. Traders may want to exercise short-term caution, but for long-term investors these dips are often opportunities to buy high-quality stocks at more attractive prices. Insider Buying Can Point the Way One reliable indicator in times like these is insider buying. Green suggests paying attention when officers and directors—people with access to non-public financials—are putting their own money into their companies. He recommends tracking insider trading activity to see which stocks executives are buying, not just selling. While insiders aren’t always right, their actions can be a useful signal when markets are in flux. A Biotech Breakout to Watch: GRAIL One sector Green is focused on right now is biotech, where artificial intelligence is helping accelerate drug development and reduce costs. He highlighted one company in particular: GRAIL (NASDAQ: GRAL). Spun off from Illumina, GRAIL developed the Galleri Test, a blood-based screening that can detect more than 50 types of cancer from a single sample. Green has used the test himself and says it’s "a good feeling" to know you’re clear of so many deadly diseases, including cancers like pancreatic that are often diagnosed late. With FDA fast-track status and potential insurance reimbursement ahead, Green views GRAIL’s roughly $3 billion market cap as only a starting point. The Biotech Risk—and Big Pharma's Appetite Biotech carries risk: most drugs never make it through all phases of trials. Still, larger pharmaceutical companies such as Merck (NYSE: MRK), Pfizer (NYSE: PFE), and Bristol Myers (NYSE: BMY) actively acquire promising small caps to replace expiring patents. Green pointed to Johnson & Johnson (NYSE: JNJ) as a recent example: the company invested in a private prostate cancer drug before FDA approval—underscoring how aggressive Big Pharma can be when clinical trials look promising. He also believes biotech is especially compelling now because healthcare is largely recession-resistant. Whether the economy is expanding or contracting, people still need care. For investors seeking steadier demand and less drama than high-flying AI names, sectors like healthcare, utilities, consumer staples, and food companies can offer more stability. The American Dream Is Still Possible—But Mindset Matters Despite economic challenges, Green argues the American Dream is far from dead. He wrote The American Dream to counter the narrative that it's out of reach, noting his surprise at polls showing nearly 70% of Americans believe it's no longer attainable. In reality, he says, access to low-cost investment tools, no-commission trading, and abundant information makes building wealth more accessible than ever. The key is knowing what to do—and having the discipline to do it. He breaks it down simply: if a 25-year-old invests $190 a month in an S&P 500 index fund, they could have $1 million by age 65—tax-free in a Roth IRA. No extreme frugality required. "You could eat out, take trips, and still build wealth," Green says—as long as you save and leave the money to compound. Creative Solutions for Today's Housing Market Housing may feel out of reach, but Green says there are still paths in. Mortgage rates have doubled and prices are up since the pandemic, but creative options exist. He shares his personal story of buying two houses with no money down by working directly with motivated sellers and assuming their mortgages—a method known as a "contract for deed." It might not get you the perfect house immediately, but it can help you start building equity sooner than you expect. Stay Focused on the Long Game Volatile markets come and go. What matters is how you respond. Whether it’s tracking insider moves, exploring high-upside sectors like biotech, or simply believing in your ability to build a financial future, Green’s message is clear: the American Dream is still within reach. You just have to keep your eyes on it—and take the next right step.
| 
